IBI3022

N/A

Report date: 2026/04/15 20:02:38

Base Information

Drug NameIBI3022
Drug Alias NameIBI3022IBI-3022
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Trop-2Anti-V-set domain-containing T-cell activation inhibitor 1DNA topoisomerase I inhibitors
TargetsTumor-associated calcium signal transducer 2V-set domain-containing T-cell activation inhibitor 1DNA topoisomerase I
Therapy Area/IndicationsGenital Neoplasms, Female
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesInnovent Biologics(Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesInnovent Biologics(Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsGenital Neoplasms, Female
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A